Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 53, Issue 9, Pages 2330-2333Publisher
SPRINGER
DOI: 10.1007/s10620-007-0183-9
Keywords
carnitine; hepatic encephalopathy; cirrhosis; portal hypertension
Categories
Ask authors/readers for more resources
Hepatic encephalopathy (HE) is a significant cause of morbidity and mortality in patients with advanced chronic liver disease. Current therapies are associated with inconvenient side-effects, high cost, and incomplete efficacy. The quanternary ammonium compound L-acyl-carnitine has been suggested as a potent, low-cost, and safe alternative therapy for patients with cirrhosis and HE. A systematic review of the literature assessing the use of carnitine in the treatment of HE identified three high-quality human trials for review. Analysis of the selected carnitine trials compared to currently accepted therapies suggests that L-acyl-carnitine is promising as a safe and effective treatment for HE, and further trials of this drug are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available